ReviewBMC medicine2017
What makes gouty inflammation so variable?
Review in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 87 citations in OpenAlex.
- Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators.Scientific reports · 2024Trial
- Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2024Trial
- Medicinal Value ofInternational journal of molecular sciences · 2026Review
- Treat-to-Target Urate-lowering Therapy: Lessons Learned from the STOP Gout Study.Current rheumatology reports · 2026Review
- The role of high large unstained cell percentages in ongoing inflammation in the intercritical gout.Joint diseases and related surgery · 2025Article
- The spectrum of lysosomal stress and damage responses: from mechanosensing to inflammation.EMBO reports · 2025Review
- Correlation of systemic immune inflammation and serum uric acid with gout: based on NHANES.Clinical rheumatology · 2025Article
- Spinal gout recovery with urate-lowering therapy: A case report.Clinical case reports · 2025Article
- Correlation of systemic immune inflammation and serum uric acid with gout: based on NHANES.Clinical rheumatology · 2025Article
- Unraveling the pathological biomineralization of monosodium urate crystals in gout patients.Communications biology · 2024Article
- CD8 T cell-derived perforin regulates macrophage-mediated inflammation in a murine model of gout.Clinical rheumatology · 2024Article
- Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement activation and inflammation modulators.Research square · 2024Article
- The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Sustained xanthine oxidase inhibitor treat to target urate lowering therapy rewires a tight inflammation serum protein interactome.Research square · 2024Article
- Relief of gouty arthritis in rats by total saponins fromExperimental and therapeutic medicine · 2023Article
- Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.Rheumatology (Oxford, England) · 2023Article
- Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Effects of alcohol on the symptoms of gouty arthritis and taxonomic structure of gut microbiota in C57BL/6 mice.Frontiers in microbiology · 2023Article
- Anti-inflammation is an important way that Qingre-Huazhuo-Jiangsuan recipe treats acute gouty arthritis.Frontiers in pharmacology · 2023Article
- Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing a progressively increasing public health problem. Flares can be complex and expensive to treat, partly due to the frequent comorbidities. Unmet needs in gout management are more pressing given the markedly increasing gout flare hospital admission rates. In addition, chronic gouty arthritis can cause joint damage and functional impairment. This review addresses new knowledge on the basis for the marked, inherent variability of responses to deposited urate crystals, including the unpredictable and self-limited aspects of many gout flares. Specific topics reviewed include how innate immunity and two-signal inflammasome activation intersect with diet, metabolism, nutritional biosensing, the microbiome, and the phagocyte cytoskeleton and cell fate. The paper discusses the roles of endogenous constitutive regulators of inflammation, including certain nutritional biosensors, and emerging genetic and epigenetic factors. Recent advances in the basis of variability in responses to urate crystals in gout provide information about inflammatory arthritis, and have identified potential new targets and strategies for anti-inflammatory prevention and treatment of gouty arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.